Tag: MSSNY eNews April 16

.

Colleagues:

Your MSSNY physician leadership met with our NY Congressional delegation in February 2021 with a focus on preventing the implementation of the ill-timed impending 2% Medicare Cuts scheduled for April 1.  Numerous grassroots letters were sent by NYS physicians and this week our collective efforts paid dividends. The US House of Representatives approved legislation to extend the 2% Medicare sequester moratorium until 2022 and President Biden signed it into law late Wednesday.

The 21st Century Cures Act’s information-blocking provision is now in effect and requires physicians to make available medical information such as labs tests, clinical notes and medication lists to patients. The Office of the National Coordinator for Health Information Technology (ONC) recently implemented regulations directing physicians to immediately release information to patients, in many cases, prior to the physician reviewing the information and without regard to whether such release could be mentally or emotionally distressing to the patient. While there has been strong support for patient access, a variety of concerns with automatically and immediately releasing all reports and office notes have been raised by MSSNY and throughout the country. The AMA is advocating to revise the sub-regulatory guidance to mitigate the unintended consequences of the OCR’s current policy and ONC’s information blocking regulations and needs our NYS real world examples. Please send these to Ela Cameron Ela.Cameron@ama-assn.org by April 30.

Last week I announced the numerous MSSNY Budget “victories.”  The most notable will prevent thousands of dollars of new costs for the 17,000 physicians participating in the NYS Excess Malpractice Insurance Program; protection of due process rights for all physicians; and Essential Plan enhancements benefiting more than 800,00 New Yorkers.

Advocacy in action takes dollars and with the recent “wins” serving as strong coat tails and numerous important MSSNY legislative priorities, it is time to shore up the MSSNY PAC to continue to be able to strongly and effectively advocate on behalf of patients and physicians.  If you have not already contributed, please do so now.  Any amount is helpful and appreciated. If you have already donated, please consider an additional contribution or a contribution on behalf of your practice or medical staff. Contribute to MSSNY PAC here.

Thank you for doing your part to influence positive steps forward in NY healthcare.  Together, we are Advocacy in Action—stronger, louder, and more effective.

Bonnie Litvack, MD
MSSNY President

MSSNY Weekly Podcast

Statement of MSSNY President Bonnie Litvack, MD, in Response to Enactment of State Budget
“In adopting the 2021-22 State Budget, physicians thank the New York State Assembly and Senate leadership for their efforts to restore numerous steep health care cuts that had been advanced in the Executive Budget, and the Governor for agreeing with the restoration of these cuts.  Because the COVID pandemic has caused historic drops in patient visits and revenue for physicians over the last year, there could not have been a worse time to cut Medicaid as well as other essential programs that help to preserve patient access to needed care such as the Excess Medical Malpractice Insurance Program.

“Physicians also appreciate the collective efforts of the Governor and Legislature to enhance other programs that provide needed health insurance coverage to New Yorkers, including the Essential Plan.  We look forward to working with the Senate, Assembly and Governor in additional collaborative efforts to ensure New Yorkers receive the care they need.”

For a full rundown of the many important actions taken by the State Legislature in adoption of the State Budget of impact to physicians, please click My Dear Father and MSSNY Milestones. (DIVISION OF GOVERNMENTAL AFFAIRS)

Administration of J and J Covid-19 Vaccine is Suspended; NYS Vaccination Rate Continues to Increase
This week, the CDC and FDA issued a statement recommending a pause in the use of the Johnson & Johnson vaccine out of an abundance of caution. New York State will follow the CDC and FDA recommendation and pause the use of the Johnson & Johnson vaccine statewide while these health and safety agencies evaluate next steps.  The CDC has indicated that this suspension will be at least one week.  The New York State Department of Health is has said that those adverse reactions appear to be rare.

As of April 15, 2021, 26.4 % of New Yorkers have completed the vaccine series and 23.6% of Americans have been fully immunized. 39.6% of New Yorkers have received at least one dose and 48.3% of Americans have received one dose.   All providers can vaccinate any New Yorker, including those with comorbidities or underlying conditions, and individuals 16+. Enrolled providers other than pharmacies may vaccinate any eligible individual. Pharmacies must prioritize K-12 school faculty and staff and childcare workers but are also authorized to vaccinate individuals aged 30 and older and individuals with comorbidities.

Physicians and patients can determine eligibility and make an appointment to receive the vaccine by going to. (CLANCY) 

US House Passes Legislation to Prevent 2% Medicare Cut Until 2022
This week the US House of Representatives overwhelmingly approved legislation to extend until the end of the year the 2% Medicare sequester moratorium that had expired on April 1. +This bill to prevent ill-timed Medicare cuts to physicians and other care providers then was signed into law by President Biden.

The Centers for Medicare & Medicaid Services has been holding off on processing April Medicare claims to avoid making payments with reduced amounts.  Prevention of these cuts was a significant focus in the meetings that MSSNY physician leadership had with the New York Congressional delegation in late February.  MSSNY physician leaders made the compelling case that the ongoing financial travails impacting medical practice in New York and across the country necessitated the elimination of short-sighted medical cuts that will adversely impact patient access to needed care. (AUSTER)

Please Contact Your Legislators to Urge Revisions to “Consolidated Billing” Legislation
Physicians are urged to contact their Assembly members and Senators to urge them to substantially revise A.3470-A/S.2521-A, “The Patient Medical Debt Reduction Act”. Click here to contact your legislators today! Click Here.

While there are many components to this well-intended legislation, there is a seriously problematic component which would prohibit a physician or other provider with any “financial or contractual relationship” with a hospital from separately billing a patient for a course or episode of treatment in the hospital. While it doesn’t appear to prohibit continued separate billing to insurance companies or other payers, a single hospital-physician bill would be required when a bill is sent to a patient for costs not covered by the patient’s insurance, such as collection of a deductible. It would also require such consolidated bill to be sent within 7 days of a patient’s discharge from the hospital, before there is any clarity as to what expenses will actually be covered by a patient’s insurance.

If this bill were to pass and this provision not amended, it would put non-employed physicians at the mercy of the hospitals where they practice since the legislation does not specify how payments to hospitals from this “single bill” would then be distributed to these physicians.  In an era when patients’ insurance policies regularly impose enormous deductibles, it would likely force even more physicians to sell their practices and become employees of hospitals in response to the helpless position many physicians would find themselves.  Other physicians may leave the state altogether.  The impact of this prohibition will fall most adversely on physicians who are on the front lines of the pandemic, many of whom are facing an enormous drop in patient volume due to a significant amount of delayed care.       (AUSTER)

Requirement to Co-prescribed Opioid Antagonist Moving in New York State Legislature
Senate Bill 2966, sponsored by Sen. Pete Harckham, chair of the Senate Committee on Alcoholism and Substance Abuse, is on the Senate Health Committee.  This measure would require that prescribers, who prescribe opioids for the first time for a patient in a calendar year, also co-prescribe an opioid antagonist with the prescription.  While MSSNY agrees that co-prescription of naloxone is an appropriate step for many patients prescribed opioid medications, it is very concerned with an across-the-board mandate.     Its companion measure, A. 336, sponsored by Assembly Edward Braunstein, is currently in the Assembly Ways and Means Committee.

The Medical Society believes that this legislation is unnecessary since New York State laws have been passed that allows non-medical persons to administer naloxone to another individual to prevent an opioid/heroin overdose from becoming fatal. Physicians and other prescribers can already provide patients with either a non-patient specific script or a patient specific script for naloxone. New York State is one of the four states that currently require electronic prescribing for controlled substances and has had this requirement since 2016.

This means that the co-prescription of the opioid antagonist will automatically go to the pharmacy and the patient will be charged a co-pay (if their insurance covers the prescription) or the full price for the naloxone script.  Physicians are encouraged to contact members of the Senate Health Committee by calling 518-455-2800.  Senator committee members are: Senators Gustavo Rivera, Patrick Gallivan, Brian Benjamin, Alessandra Biaggi, Phil Boyle, Samra Brouk, Brad Hoylman, Todd Kaminsky, Rachel May, Peter Oberacker, Edward Rath, Sean Ryan, Julia Salazar, Daniel Stec, and Kevin Thomas. (CLANCY)

Bill to Expand Podiatry Scope Moving in the Senate
S.2019 (Jackson) to expand the scope of practice of podiatrists is on the Senate Higher Education Committee next week.  MSSNY along with the New York State Society of Orthopedic Surgeons and several other specialty societies are opposed to this legislation.  While the bill purports to make “technical changes” to the practice of podiatry, it actually has a far greater impact, including: Allowing those in training not to have direct/onsite supervision by another podiatrist or orthopaedic surgeon as they learn and practice ankle surgery; permitting ANY podiatrist to care for wounds above the foot and ankle that are not related to the patient’s original course of treatment; Lowering the threshold for education and training for those seeking advanced ankle surgery privileges in contrast with standards deemed acceptable by the State Department of Education and agreed upon by the professions; and authorize podiatrists to practice up to the knee and outside of their scope of practice. Physicians are urged to contact their Senators to oppose this legislation 518-455-2800. (AUSTER)

Bill to Allow Pharmacists to Perform Non-invasive Laboratory Tests
Legislation (S.2529, Rivera) that would allow pharmacists to perform non-invasive laboratory tests without physician coordination is on the Senate Health Committee.   This measure would add pharmacists to the list of licensed health care professionals authorized under public health law to perform non-invasive laboratory tests as an adjunct to their professional services. MSSNY is opposed to this measure, as this measure does not provide the continuum of care that has become essential and expected in today’s medical practice, and would lead to siloed, rather than integrated care.

MSSNY is concerned that this legislation is a back-door attempt to allow for the establishment of the retail clinics within pharmacies and would undermine the development of physician-led “medical homes”. Physicians are encouraged to contact members of the Senate Health Committee by calling 518-455-2800.  Senate committee members are:   Senators Gustavo Rivera, Patrick Gallivan, Brian Benjamin, Alessandra Biaggi, Phil Boyle, Samra Brouk, Brad Hoylman, Todd Kaminsky, Rachel May, Peter Oberacker, Edward Rath, Sean Ryan, Julia Salazar, Daniel Stec, and Kevin Thomas.            Its companion measure, A.3033, is in the Assembly Higher Education Committee.     (CLANCY)

Preparing for Future Public Health Emergencies
Governor Andrew Cuomo and the New York State Department of Health have announced a free online public health training course to help build public health awareness.  The course was developed by Cornell University in partnership with New York State.  The free course informs on public health preparedness, COVID-19, the vaccines and is an interesting and engaging tool to educate the public and empower more New Yorkers to be better informed with accurate information. Through this course, New Yorkers can become Citizen Public Health Leaders and serve as reliable sources in their family. (CLANCY)

DATE CHANGE: Social Media in Medicine is Now Wednesday, May 5 at 6 PM ET
MSSNY Vice President Parag H. Mehta, MD and MSSNY YPS Chair Daniel E. Choi, MD present Social Media in Medicine: A Beginners Guide for Physicians.
Register for Social Media Webinar

When: May 5, 2021 at 6:00 PM Eastern Time

After registering, you will receive a confirmation email containing information about joining the meeting.

Topics Include:

• Introduction to popular social media physician communities: #MedTwitter,
  Instagram, YouTube, TikTok
• How to establish a social media presence and grow your audience
• Common terminology e.g. Twitter handle, hashtag
• Scheduling posts
• How social media can be harnessed for effective patient education, practice growth, and advocacy
• Best ways to connect with patients and colleagues on social media
• Pitfalls of social media as a physician
• What not to do on social media

Scams Against Medical Professionals CME Webinar: Wednesday, April 21, 2021 at 6:00 PM
Join the Suffolk County Medical Society, Suffolk Academy of Medicine and
MLMIC Insurance Company on Wednesday, April 21, 2021 at 6:00 PM for this in-depth discussion on phishing, practice awareness, law enforcement procedures, preventative steps and more!

The goal of this webinar is to increase physician awareness of the opioid crisis and scammers impersonating DEA agents.  The risks of security violations, privacy breaches, and cyberattacks presented by the expansion of health technology will also be analyzed.

Register for Scams Against Medical Professionals Webinar 

Learning Objectives:

• Review the mission of the Drug Enforcement Agency (DEA) Office of Diversion Control.
• Recognize the converging coronavirus and opioid health crises.
• Assess the prescription drug abuse problem in this country.
• Describe the issue of scammers impersonating DEA agents and measures to best deter them.
• Identify the security risks presented by healthcare technology.
• Implement strategies to reduce risks of a privacy breach or cyberattack in healthcare.

MLMIC is accredited by the Medical Society of the State of New York (MSSNY) to provide continuing medical education for physicians.

MLMIC designates this live internet activity for a maximum of 1.5 AMA PRA Category 1 CME Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the program.

Do You Know an Outstanding Physician? MSSNY Now Accepting Nominations for the Albion O. Bernstein, MD Award

“…the physician, surgeon or scientist who shall have made the most widely beneficial discovery or developed the most useful method in medicine, surgery or in the prevention of disease in the twelve months prior to December, 2020.” 

This award was endowed by the late Morris J. Bernstein in memory of his son, a physician who died in an accident while answering a hospital call in November, 1940.

The $2,000 award will be presented to the recipient during a MSSNY Council Meeting.

Nominations must be submitted on an official application form and must include the nominator’s narrative description of the significance of the candidate’s achievements as well as the candidate’s curriculum vitae, including a list of publications or other contributions.

Deadline for applications is June 9, 2021. To request an application, please contact: 

Committee on Continuing Medical Education
Miriam Hardin, PhD, Manager, Continuing Medical Education
Medical Society of the State of New York
99 Washington Avenue, Suite 408
Albany, NY 12210
518-465-8085
 mhardin@mssny.org

CDC Health Alert: Cases of Cerebral Venous Sinus Thrombosis with Thrombocytopenia after Receipt of the Johnson & Johnson COVID-19 Vaccine
As of April 12, 2021, approximately 6.85 million doses of the Johnson & Johnson (J&J) COVID-19 vaccine (Janssen) have been administered in the United States. The Centers for Disease Control and Prevention (CDC) and the U.S. Food and Drug Administration (FDA) are reviewing data involving six U.S. cases of a rare type of blood clot in individuals after receiving the J&J COVID-19 vaccine that were reported to the Vaccine Adverse Events Reporting System (VAERS). In these cases, a type of blood clot called cerebral venous sinus thrombosis (CVST) was seen in combination with low levels of blood platelets (thrombocytopenia).

All six cases occurred among women aged 18–48 years. The interval from vaccine receipt to symptom onset ranged from 6–13 days. One patient died. Providers should maintain a high index of suspension for symptoms that might represent serious thrombotic events or thrombocytopenia in patients who have recently received the J&J COVID-19 vaccine. When these specific type of blood clots are observed following J&J COVID-19 vaccination, treatment is different from the treatment that might typically be administered for blood clots. Based on studies conducted among the patients diagnosed with immune thrombotic thrombocytopenia after the AstraZeneca COVID-19 vaccine in Europe, the pathogenesis of these rare and unusual adverse events after vaccination may be associated with platelet-activating antibodies against platelet factor-4 (PF4), a type of protein. Usually, the anticoagulant drug called heparin is used to treat blood clots. In this setting, the use of heparin may be harmful, and alternative treatments need to be given.

CDC will convene an emergency meeting of the Advisory Committee on Immunization Practices (ACIP) on Wednesday, April 14, 2021, to further review these cases and assess potential implications on vaccine policy. FDA will review that analysis as it also investigates these cases. Until that process is complete, CDC and FDA are recommending a pause in the use of the J&J COVID-19 vaccine out of an abundance of caution. The purpose of this Health Alert is, in part, to ensure that the healthcare provider community is aware of the potential for these adverse events and can provide proper management due to the unique treatment required with this type of blood clot.

Background

VAERS is a national passive surveillance system jointly managed by CDC and FDA that monitors adverse events after vaccinations. The six patients (after 6.85 million vaccine doses administered) described in these VAERS reports came to attention in the latter half of March and early April of 2021 and developed symptoms a median of 9 days (range = 6–13 days) after receiving the J&J COVID-19 vaccine. Initial presenting symptoms were notable for headache in five of six patients, and back pain in the sixth who subsequently developed a headache. One patient also had abdominal pain, nausea, and vomiting. Four developed focal neurological symptoms (focal weakness, aphasia, visual disturbance) prompting presentation for emergency care. The median days from vaccination to hospital admission was 15 days (range = 10–17 days). All were eventually diagnosed with CVST by intracranial imaging; two patients were also diagnosed with splanchnic* and portal vein thrombosis.

Unusual for patients presenting with thrombotic events, all six patients showed evidence of thrombocytopenia (<150,000 platelets per microliter of blood), consistent with a condition known as thrombotic thrombocytopenia, with platelet nadir counts ranging from 10,000 to 127,000 during their hospitalizations. Four patients developed intraparenchymal brain hemorrhage and one subsequently died. All data presented in this HAN are preliminary and investigations of these VAERS reports are ongoing. The Clinical Immunization Safety Assessment (CISA) project which includes experts in infectious disease and hematology are also reviewing these cases. To date, VAERS has received no reports of CVST with thrombocytopenia among persons who received either of the two mRNA-based COVID-19 vaccines.

These reports following the J&J COVID-19 vaccine are similar to reports of thrombotic events with thrombocytopenia after receipt of the AstraZeneca COVID-19 vaccine in Europe. Both vaccines contain replication-incompetent adenoviral vectors (human [Ad26.COV2.S] for J&J and chimpanzee [ChAdOx1] for AstraZeneca) that encode the spike glycoprotein of SARS-CoV-2, the virus that causes COVID-19.

Based on studies conducted among the patients diagnosed with immune thrombotic thrombocytopenia after the AstraZeneca COVID-19 vaccine in Europe, the pathogenesis of these rare and unusual adverse events may be associated with platelet-activating antibodies against platelet factor 4 (PF4). Anti-PF4, also known as heparin-PF4 antibody, can induce thrombotic thrombocytopenia in a small percentage of persons exposed to heparin. However, none of the cases reported from Europe had recent heparin exposure. As with heparin-induced thrombocytopenia, the administration of the anticoagulant heparin should be avoided in patients with potential vaccine-associated immune thrombotic thrombocytopenia (VITT), unless heparin-induced thrombocytopenia (HIT) testing is negative. Non-heparin anticoagulants and high-dose intravenous immune globulin should be considered in treatment of patients who present with immune-mediated thrombotic events with thrombocytopenia after J&J COVID-19 vaccination. Consultation with hematology specialists is strongly recommended.

* The term ‘splanchnic circulation’ describes the blood flow to the abdominal gastrointestinal organs including the stomach, liver, spleen, pancreas, small intestine, and large intestine.

Recommendations
For Clinicians

1. Pause the use of the J&J COVID-19 vaccine until the ACIP is able to further review these CVST cases in the context of thrombocytopenia and assess their potential significance.
2. Maintain a high index of suspension for symptoms that might represent serious thrombotic events or thrombocytopenia in patients who have recently received the J&J COVID-19 vaccine, including severe headache, backache, new neurologic symptoms, severe abdominal pain, shortness of breath, leg swelling, petechiae (tiny red spots on the skin), or new or easy bruising. Obtain platelet counts and screen for evidence of immune thrombotic thrombocytopenia.
3. In patients with a thrombotic event and thrombocytopenia after the J&J COVID-19 vaccine, evaluate initially with a screening PF4 enzyme-linked immunosorbent (ELISA) assay as would be performed for autoimmune HIT. Consultation with a hematologist is strongly recommended.
4. Do not treat patients with thrombotic events and thrombocytopenia following receipt of J&J COVID-19 vaccine with heparin, unless HIT testing is negative.
5. If HIT testing is positive or unable to be performed in patient with thrombotic events and thrombocytopenia following receipt of J&J COVID-19 vaccine, non-heparin anticoagulants and high-dose intravenous immune globulin should be strongly considered.
6. Report adverse events to VAERS, including serious and life-threatening adverse events and deaths in patients following receipt of COVID-19 vaccines as required under the Emergency Use Authorizations for COVID-19 vaccines.

For Public Health

1. Pause the use of the J&J COVID-19 vaccine in public health clinics until the ACIP is able to further review these CVST cases in the context of thrombocytopenia and assess their potential significance.
2. Encourage healthcare providers and the public to report all serious and life-threatening adverse events and deaths following receipt of COVID-19 vaccines to VAERS as required under the EUAs for COVID-19 vaccines.
3. Disseminate this alert to healthcare providers in your jurisdictions.

For the Public

1. If you have received the J&J COVID-19 vaccine and develop severe headache, abdominal pain, leg pain, or shortness of breath within three weeks after vaccination, contact your healthcare provider, or seek medical care.
2. Report adverse events following receipt of any COVID-19 vaccine to VAERS.
3. If you are scheduled to receive the J&J vaccine, please contact your healthcare provider, vaccination location, or clinic to learn about additional vaccine availability.

For More Information

Frequently asked questions about VAERS reporting for COVID-19 vaccines

CDC Identifies About 5,800 Breakthrough Cases of COVID-19 Infection Among Americans Who Have Been Fully Vaccinated
The Wall Street Journal reports the CDC has identified about 5,800 breakthrough cases of COVID-19 infection among more than 66 million Americans who have been fully vaccinated against COVID-19. Based on this data, the CDC says breakthrough cases of infection occur in 0.008% of people who have been fully vaccinated.

COVID-19 Medicare Part B Advanced Payment, Repayment and Recoupment Process                                         
If you requested accelerated or advanced payments from Medicare due to the COVID-19 public health emergency, this learning session is for you. CMS expanded the accelerated and advance payment program for financial hardship relief during the COVID-19 public health emergency. Accelerated or advanced payments need to be repaid to the Medicare Trust Fund. During this webinar, we will review the repayment and recoupment process and address your questions.

Register here

MSSNY Medical Matters Program on Mental Health of Children and Teens During COVID
Registration now open
Medical Matters: COVID-19 & Mental Health of Children and Teens
Date: April 21, 2021 @ 7:30am 

The COVID-19 pandemic has affected the mental health of the entire population.  Learn more about how children and teens have been affected by registering for Medical Matters: COVID-19 & Mental Health of Children and Teens. This webinar will take place on Wednesday, April 21^st at 7:30 am.  Linda Chokroverty, MD will serve as faculty for this program.  Click here to register for this webinar.

Educational objectives

• Identify normal stressors impacting children and teens and those that have resulted from the COVID-19 pandemic
• Examine what is known so far about the mental health impact of COVID-19 on children and teens
• Describe resources to assist children and teens during the COVID-19 pandemic
• Appraise the scope of COVID-19’s long term mental health impact on children and teens

The Medical Society of the State of New York is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Medical Society of the State of New York designates this live activity for a maximum of 1.0 AMA PRA Category 1 credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. (HOFFMAN)

Veterans Matters: Military Culture: Everything Physicians Need to Know about Veterans as Patients Webinar

Registration Now Open

Thursday, April 22^nd @ 7:30 am

The Medical Society of the State of New York is hosting a Continuing Medical Education (CME) program entitled Veterans Matters: Military Culture: Everything Physicians Need to Know about Veterans as Patients live webinar on Thursday, April 22, 2021 at 7:30 am.

Click HERE to register for the program! View the program flyer HERE.

When:       April 22, 2021 at 7:30 am
Faculty:     Lt. Colonel Lance Allen Wang (Ret.) & Sharran Chambers-Murphy, Desert Storm-era Veteran

Educational Objectives:

• Describe the unique aspects of military culture and how they impact patients     who are veterans;
• Explain the Dwyer Peer-to-Peer program as a resource to assist veteran patients re-acclimating from a group to an individual mentality; and
• Review and identify resources to improve physician’s ability to fully treat veterans who are transitioning back to civilian life.

For more information, contact Jangmu Sherpa at jsherpa@mssny.org or call (518) 465-8085.

The Medical Society of the State of New York is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Medical Society of the State of New York designates this live activity for a maximum of 1.0 AMA PRA Category 1 credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity. (SHERPA)

Webinar for Physicians Applying to PCF Model on April 31
Physicians considering applying for the PCF model to start in 2022 are invited to register now for a webinar to be offered Tuesday, April 13, from 6:00-7:00 pm ET by the American Medical Association, American College of Physicians, American Academy of Family Physicians, and the CMS Innovation Center. PCF is open to medical practices that provide primary care services in 26 regions across the country, with an application deadline of April 31, 2021.

The live webinar will allow participants to hear from CMS and medical society experts about the model and how participation could affect their practice revenues. Additional details, including the request for applications, a map of the 26 regions, and lists of the practices and other payors that are participating as part of the 2021 cohort are available on the CMS Primary Care First website.

MSSNY Veterans Matters Program: Substance Use Disorders (SUDs) in Veterans Webinar
Registration Now Open – Wednesday, May 12^th @ 7:30 am

The Medical Society of the State of New York is hosting a Continuing Medical Education (CME) program entitled Veterans Matters: Substance Use Disorders (SUDs) in Veterans live webinar on Wednesday, May 12, 2021 at 7:30 am.

Click HERE to register for the program! View the program flyer HERE

When:                 May 12, 2021 at 7:30 am
Faculty:               Thomas Madejski, MD

Educational Objectives:

• Identify Substance Use Disorders (SUDs) in veterans
• Discuss evidence-based psychosocial strategies to treat veterans with SUDs
• Discuss Medication Assisted Treatment (MAT) for veterans with alcohol or opioid use disorders
• Identify barriers to diagnosis and treatment of SUDs in veterans and methods to overcome them

For more information, contact Jangmu Sherpa at jsherpa@mssny.org or call (518) 465-8085.

The Medical Society of the State of New York is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Medical Society of the State of New York designates this live activity for a maximum of 1.0 AMA PRA Category 1 credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity. (SHERPA)

Classified Ads Available for:

Physicians’ search services • allied medical placements • locum tenens • practice valuation • practice brokerage • practice consulting • real estate

For help, information or to place your ad, call Christina Southard 516-488-6100 x355 • fax 516-488-2188

For the MSSNY 2021 Ad Rate Sheet, please click here.

.Two Offices Available for Rent in Established SoHo Primary Care Practice
Newly constructed loft space. Dedicated private waiting area available.  This space is ideal for individual psychiatry, psychology, social work, physical therapy, or acupuncture services. Potential to work with existing Primary Care Practice as a referral source. Centrally located in the heart of SoHo, close to all subways. Available 7 days/week.
Contact: SpringPrimaryCare@gmail.com.